AKTX

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Akari Therapeutics PLC

NASDAQ | AKTX

0.48

USD

+$0.00

(

+0.00%

)

At Close (As of Nov 28, 2025)

$16.96M

Market Cap

0

P/E Ratio

0

EPS

$1.73

52 Week High

$0.41

52 Week Low

HEALTHCARE

Sector

AKTX Chart

Recent Chart
Price Action

AKTX Technicals

Tags:

AKTX Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$14K
Total Revenue $0
Cost Of Revenue $14K
Costof Goods And Services Sold $14K
Operating Income -$22M
Selling General And Administrative $9.7M
Research And Development $7M
Operating Expenses $22M
Investment Income Net -
Net Interest Income -$236K
Interest Income $8K
Interest Expense $244K
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $14K
Income Before Tax -$20M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$20M
Comprehensive Income Net Of Tax -
Ebit -$20M
Ebitda -$20M
Net Income -$20M

Revenue & Profitability

Earnings Performance

AKTX Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $51M
Total Current Assets $3M
Cash And Cash Equivalents At Carrying Value $2.6M
Cash And Short Term Investments $2.6M
Inventory -
Current Net Receivables $201K
Total Non Current Assets $48M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets $39M
Intangible Assets Excluding Goodwill $39M
Goodwill $8.4M
Investments -
Long Term Investments -
Short Term Investments -
Other Current Assets $152K
Other Non Current Assets -
Total Liabilities $28M
Total Current Liabilities $20M
Current Accounts Payable $12M
Deferred Revenue -
Current Debt -
Short Term Debt $3.3M
Total Non Current Liabilities $8.4M
Capital Lease Obligations -
Long Term Debt -
Current Long Term Debt $3.3M
Long Term Debt Noncurrent -
Short Long Term Debt Total $3.3M
Other Current Liabilities $4.2M
Other Non Current Liabilities $383K
Total Shareholder Equity $22M
Treasury Stock -
Retained Earnings -$247M
Common Stock $5.3M
Common Stock Shares Outstanding $12K

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$13M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $14K
Capital Expenditures $0
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment $382K
Cashflow From Financing $11M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$20M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$14K
Total Revenue $0
Cost Of Revenue $14K
Costof Goods And Services Sold $14K
Operating Income -$22M
Selling General And Administrative $9.7M
Research And Development $7M
Operating Expenses $22M
Investment Income Net -
Net Interest Income -$236K
Interest Income $8K
Interest Expense $244K
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $14K
Income Before Tax -$20M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$20M
Comprehensive Income Net Of Tax -
Ebit -$20M
Ebitda -$20M
Net Income -$20M

AKTX News

AKTX Profile

Akari Therapeutics PLC Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Akari Therapeutics PLC is a London-based clinical-stage biopharmaceutical company dedicated to developing innovative therapies for autoinflammatory diseases by targeting the complement and leukotriene pathways. The company boasts a diverse pipeline of drug candidates aimed at addressing significant unmet medical needs and enhancing patient outcomes. With a commitment to leveraging its scientific expertise through strategic partnerships, Akari Therapeutics is well-positioned to effectively navigate the complexities of clinical development and deliver transformative therapies to market.

LPTX
+368.57%
$2.05
VHAI
0.00%
$0.00
KTTA
+51.88%
$1.61
VINE
+10.76%
$0.39
NVDA
-1.80%
$177.00
AMZE
+19.82%
$0.47
TLRY
-22.27%
$0.80
BITF
+12.25%
$3.48
IPG
-1.95%
$24.57
INTC
+9.08%
$40.15
YGMZ
-9.59%
$0.11
AXDX
-61.36%
$0.03
TSLA
+1.71%
$426.58
BYND
-4.59%
$0.97
BMNR
+4.53%
$33.18
ADAP
-15.14%
$0.05
RUBI
-26.17%
$0.15
ASST
-0.88%
$1.12
PLUG
+1.51%
$2.01
CLSK
+11.97%
$15.06
SOND
-23.45%
$0.12
WBD
+4.00%
$23.88
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
AAL
+0.86%
$14.05
INHD
-0.97%
$0.22
BIYA
+10.67%
$0.27
SRM
+53.27%
$10.30
CHR
-2.55%
$0.04
ONMD
+31.69%
$1.87
SNAP
+0.37%
$7.63
WULF
+4.51%
$15.51
BULL
+6.43%
$9.26
F
+0.45%
$13.25
TWOH
0.00%
$0.00
BMNU
+3.72%
$7.79
CIFR
+7.41%
$20.56
WLGS
-5.57%
$0.04
MTSR
-0.35%
$70.50
BURU
+10.43%
$0.24
GPUS
-8.58%
$0.30
MARA
+4.18%
$11.57
VALE
+0.79%
$12.61
SOFI
+4.31%
$29.72
ONDS
-4.36%
$7.88
NIO
+1.09%
$5.51
ADTX
+21.01%
$3.80
BTG
+3.80%
$4.64
AFMD
-34.94%
$0.18
DEFT
+9.24%
$1.51
APLD
+5.05%
$24.94
BTBT
+1.15%
$2.34
KWM
+17.30%
$0.77
GOOGL
-0.26%
$319.09
PFE
0.00%
$25.71
SMX
+244.97%
$60.02
AMZN
+1.77%
$233.22
CRCL
+9.28%
$79.38
AIIO
-9.09%
$0.70
GRYP
-10.38%
$1.38
DVLT
-7.05%
$1.97
HBI
-2.20%
$6.44
ACHR
+4.79%
$7.84
MODV
-25.22%
$0.43
BAC
+1.28%
$53.67
AMD
+1.53%
$217.53
AMCR
+1.29%
$8.62
RIVN
+4.20%
$16.86
IBRX
+9.15%
$2.32
CAN
+10.07%
$1.01
GRAB
+2.34%
$5.44
RIOT
+6.97%
$16.00
IREN
-1.31%
$47.81
AG
+12.47%
$15.19
NGD
+5.92%
$8.30
ITUB
+1.82%
$7.80
AGNC
-0.66%
$10.49
KDLY
+7.20%
$0.49
DNN
+0.39%
$2.57
T
+0.69%
$26.00
VEEE
+50.56%
$2.68
YCBD
-3.44%
$0.53
NVO
+1.21%
$49.30
CRCA
+17.43%
$4.32
AMC
+5.99%
$2.43
TMC
+17.92%
$6.87
GOOG
-0.34%
$319.17
SAND
-6.04%
$12.12
BBD
+0.67%
$3.70
RIG
+1.97%
$4.38
CRWV
-1.57%
$73.12
SHOT
-74.37%
$0.39
RGTI
0.00%
$25.57
ZAPP
-46.30%
$0.15
MSFT
+1.34%
$492.01
BTE
+2.05%
$3.22
CDE
+6.08%
$17.17
SMR
+4.38%
$19.87
SNDK
+3.83%
$223.28
LPTX
+368.57%
$2.05
VHAI
0.00%
$0.00
KTTA
+51.88%
$1.61
VINE
+10.76%
$0.39
NVDA
-1.80%
$177.00
AMZE
+19.82%
$0.47
TLRY
-22.27%
$0.80
BITF
+12.25%
$3.48
IPG
-1.95%
$24.57
INTC
+9.08%
$40.15
YGMZ
-9.59%
$0.11
AXDX
-61.36%
$0.03
TSLA
+1.71%
$426.58
BYND
-4.59%
$0.97
BMNR
+4.53%
$33.18
ADAP
-15.14%
$0.05
RUBI
-26.17%
$0.15
ASST
-0.88%
$1.12
PLUG
+1.51%
$2.01
CLSK
+11.97%
$15.06
SOND
-23.45%
$0.12
WBD
+4.00%
$23.88
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
AAL
+0.86%
$14.05
INHD
-0.97%
$0.22
BIYA
+10.67%
$0.27
SRM
+53.27%
$10.30
CHR
-2.55%
$0.04
ONMD
+31.69%
$1.87
SNAP
+0.37%
$7.63
WULF
+4.51%
$15.51
BULL
+6.43%
$9.26
F
+0.45%
$13.25
TWOH
0.00%
$0.00
BMNU
+3.72%
$7.79
CIFR
+7.41%
$20.56
WLGS
-5.57%
$0.04
MTSR
-0.35%
$70.50
BURU
+10.43%
$0.24
GPUS
-8.58%
$0.30
MARA
+4.18%
$11.57
VALE
+0.79%
$12.61
SOFI
+4.31%
$29.72
ONDS
-4.36%
$7.88
NIO
+1.09%
$5.51
ADTX
+21.01%
$3.80
BTG
+3.80%
$4.64
AFMD
-34.94%
$0.18
DEFT
+9.24%
$1.51
APLD
+5.05%
$24.94
BTBT
+1.15%
$2.34
KWM
+17.30%
$0.77
GOOGL
-0.26%
$319.09
PFE
0.00%
$25.71
SMX
+244.97%
$60.02
AMZN
+1.77%
$233.22
CRCL
+9.28%
$79.38
AIIO
-9.09%
$0.70
GRYP
-10.38%
$1.38
DVLT
-7.05%
$1.97
HBI
-2.20%
$6.44
ACHR
+4.79%
$7.84
MODV
-25.22%
$0.43
BAC
+1.28%
$53.67
AMD
+1.53%
$217.53
AMCR
+1.29%
$8.62
RIVN
+4.20%
$16.86
IBRX
+9.15%
$2.32
CAN
+10.07%
$1.01
GRAB
+2.34%
$5.44
RIOT
+6.97%
$16.00
IREN
-1.31%
$47.81
AG
+12.47%
$15.19
NGD
+5.92%
$8.30
ITUB
+1.82%
$7.80
AGNC
-0.66%
$10.49
KDLY
+7.20%
$0.49
DNN
+0.39%
$2.57
T
+0.69%
$26.00
VEEE
+50.56%
$2.68
YCBD
-3.44%
$0.53
NVO
+1.21%
$49.30
CRCA
+17.43%
$4.32
AMC
+5.99%
$2.43
TMC
+17.92%
$6.87
GOOG
-0.34%
$319.17
SAND
-6.04%
$12.12
BBD
+0.67%
$3.70
RIG
+1.97%
$4.38
CRWV
-1.57%
$73.12
SHOT
-74.37%
$0.39
RGTI
0.00%
$25.57
ZAPP
-46.30%
$0.15
MSFT
+1.34%
$492.01
BTE
+2.05%
$3.22
CDE
+6.08%
$17.17
SMR
+4.38%
$19.87
SNDK
+3.83%
$223.28
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.